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Abstract
Estrogens have been implicated in the regulation of prolactin gene expression in man, although
previous studies have not defined the molecular mechanism whereby estradiol activates the human
prolactin gene promoter (hPrl). We found that estradiol induced a reproducible 1.8-fold activation
of the hPrl gene promoter, using pituitary GH3 cells stably transfected with a 5000-bp hPrl promoter
fragment linked to luciferase reporter gene. This activation was blocked by treatment with estrogen
receptor (ER) antagonists 4-hydroxytamoxifen and ICI-182,780. Promoter deletion and mutagenesis
experiments identified a functional estrogen response element (ERE) sequence 1189 bp upstream of
the transcription start site that was responsible for estrogen-mediated promoter activation. This site
differed from the consensus ERE sequence by two base pairs, one in each half-site. This ERE was
identified to be functional through binding ERα in EMSAs. Chromatin immunoprecipitation assays
confirmed ERα binding to this sequence in vivo in the absence of ligand, with increased recruitment
when cells were cultured in the presence of estradiol. When cells were treated with both estradiol
and TNFα, we observed synergistic activation of the hPrl promoter, which was mediated by the –
1189-bp ERE. Mutagenesis of this ERE abolished the promoter-activating effect not only of estradiol
but also of TNFα. These data suggest a novel, promoter-specific signaling interaction between
estrogen and TNFα signaling, which is likely to be important for prolactin regulation in vivo.
The human prolactin gene (hPrl) is located on the short arm of chromosome 6 (1) and consists
of five coding exons within a region of 10 kb. It is expressed in man in lactotroph cells in the
anterior pituitary but also in the endometrium and myometrium of the uterus and in T
lymphocytes among a number of extrapituitary sites (2-4). In pituitary cells, prolactin gene
expression is regulated in response to multiple hormonal signals by an extensive 5′-flanking
region extending 5000 bp upstream from the transcriptional start site, which contains multiple
binding sites for Pit-1 (5), whereas in extrapituitary tissues, an alternate upstream promoter
facilitates expression of an upstream noncoding exon, exon 1a (2,6).
Pituitary prolactin expression in vivo is regulated by dopamine and other hypothalamic factors
such as TRH and by an increasing number of intrapituitary factors (reviewed in Ref. 7). In
addition to a series of growth factors, such as fibroblast growth factor-2 (FGF2) and epidermal
growth factor, cytokines such as TGFβ and TNFα [acting through nuclear factor-κB (NFκB)
activation] are important regulators of lactotroph function (8,9).
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Estrogen has long been regarded as a major physiological activator of prolactin synthesis and
lactotroph proliferation (7,10) and has been implicated in the pathophysiology of
hyperprolactinemia and prolactinomas (11). 17β-Estradiol (E2) stimulates lactotroph
proliferation and activates prolactin gene expression (12,13), and rats treated with high doses
of estrogen develop pituitary lactotroph hyperplasia (7,14). E2 exerts its genomic actions
through binding estrogen receptors (ERα and ERβ), which are ligand-activated transcription
factors residing in the cytosol and translocating to the nucleus upon ligand binding. As with
many other steroid hormone receptors, ERs can either directly bind to their consensus target
DNA sequence or interact with nuclear coactivators or corepressors, thereby either enhancing
or repressing gene expression. Studies in ER knockout mice showed that loss of the ERβ had
no effect on Prl mRNA levels in the anterior pituitary, whereas ERα knockout led to loss of
Prl expression (15,16).
In this study, we show that E2 acts through ERα to activate the hPrl promoter through a
degenerate estrogen response element (ERE) sequence found at −1189 bp relative to the
transcription start site. Mutation of this site abolished estrogen activation of the promoter. This
site was able to bind ERα in EMSAs, and chromatin immunoprecipitation (ChIP) assays
demonstrated recruitment of ERα, which increased upon E2 treatment of pituitary cells. The
transcriptional effects of E2 were significantly amplified by simultaneous treatment with a
range of other hormonal stimuli, with a striking synergistic activation when E2 was combined
with TNFα. This interaction between estrogen and TNFα signaling was mediated through the
−1189-bp ERE and suggests a novel mechanism in the transcriptional regulation of the Prl
gene.
Materials and Methods
Plasmids
The hPrl5000luc plasmid used in transient transfections and stably integrated in the GH3/hPrl-
luc cell line has been previously described (17). Site mutations were induced in the hPrl5000luc
plasmid using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Cambridge, UK)
following the manufacturer's guidelines. Oligonucleotides used for mutation of the −1189-bp
ERE site mutation were mutERE sense (S), 5′-
GATGAATTTTCCTAACCTAGGCCTCAGAGTGGCTCAG-3′, and mutERE antisense
(AS), 5′-CTGAGCCACTCTGAGGCCTAGGTTAGGAAAATTCATC-3′ (underlining
represents mutated bases). For in vitro expression of recombinant ERα, the ERα coding
sequence was inserted into the pTNT vector (Promega, Southampton, UK) under the control
of the T7 promoter.
Cell culture and luciferase assays
Cells were maintained in phenol red-free DMEM with pyruvate/glutamax (Invitrogen, Paisley,
UK) and the addition of 10% fetal calf serum (Harlan Sera-Lab, Bicester, UK). With the
exception of TNFα, FGF2 (Merck Biosciences) and ICI-182,780 (Tocris), all reagents were
obtained from Sigma Chemical Co. (Poole, UK). For transient transfections, 1.2 × 106 GH3
cells were grown in 10-cm dishes for 24 h and then transfected using FuGene 6 (Roche
Molecular Biochemicals, West Sussex, UK) according to the protocol of the manufacturer.
Initially, 10% of transfected DNA comprised a pcmvβgal reporter used to control for
transfection efficiency. However, because the entire population of cells was transfected with
a single transfection master mix and subsequently split into individual wells after transfection,
we consistently noticed no inter-well variation of βgal expression, indicating equivalent
transfection efficiency between replicates. For cotransfection studies, the total amount of DNA
used was held constant by addition of empty expression vector. After 24 h, cells were
trypsinized and seeded onto 24-well plates. For luciferase assays, 1 × 105 cells per well were
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seeded in 24-well plates, serum starved for 24 h, and then stimulated as indicated. Cells were
washed twice with ice-cold PBS, and lysates (25 mM Tris/PO4 , 10 mM MgCl2, 5 mM EDTA,
15% glycerol, 0.1% Triton X-100, and 0.1 mg/ml BSA) were prepared. The luciferase activity
was measured using a Berthold Mithras 960 luminometer (Berthold Technologies, Redbourn,
UK). Four to eight replicates were analyzed for each treatment group, and experiments were
performed at least three times. Results are shown as mean ± SD fold induction of at least three
independent experiments. For statistical analysis, P values were calculated using Student's t
test or two-way ANOVA where appropriate.
Primary cultures
Fischer 344 rats were decapitated and anterior pituitaries extracted. The pituitary was then
dissected into small fragments and treated with 20 μg/ml DNase I (Sigma) and 50 μg/ml
collagenase (Sigma). Cells were resuspended phenol red-free DMEM with pyruvate/glutamax
(Invitrogen) and 10% fetal calf serum, counted, and seeded in 24-well plates at a concentration
of 1 × 105cells per well. For experiments, the fetal calf serum-containing medium was replaced
by serum-free phenol red-free DMEM supplemented with 0.25% BSA after 24 h. After an
additional 24-h incubation, cells were stimulated accordingly.
Quantitative PCR (qPCR)
For qPCR analysis, GH3 cells were grown in 25-cm2 flasks (5 × 106 cells), serum starved for
24 h, and then stimulated with 10 nM E2 and/or 10 ng/ml TNFα for the indicated times. Cells
were harvested by trypsinization and washed twice in ice-cold PBS. Total RNA was isolated
using the QIAGEN (Hilden, Germany) RNeasy kit, and cDNA was generated with the
Omniscript RT system (QIAGEN). Quantitative real-time PCR using the Stratagene Mx3000
P thermocycler and the SYBRgreen Jump Start Taq Ready Mix (Sigma) was performed as
follows: 10 min at 95 C, followed by 40 cycles of 15 sec at 95 C, 1 min at 56 C, and 30 sec at
72 C. The following primers were used: cyclophilin forward 5′-
TTTTCGCCGCTTGCTGCAGAC-3′ and reverse 5′-
CACCCTGGCACATGAATCCTGGA-3′; rat prolactin forward 5′-
AGCCAAGTGTCAGCCCGGAAAG-3′ and reverse 5′-
TGGCCTTGGCAATAAACTCACGA-3′. This resulted in amplicons of 217 and 227 bp,
respectively. The dissociation curves of used primer pairs showed a single peak, and samples
after PCR had a single DNA band of the expected size in an agarose gel. Cyclophilin was used
as a housekeeping gene for normalization. Data are shown as average ± SD of three independent
experiments.
EMSA
Recombinant ERα was produced by the TNT in vitro transcription/translation assay (Promega)
according to the manufacturer's instructions using a pTNT-ERα plasmid. Electrophoretic
assays were performed in a 20-μl reaction containing binding reaction buffer [20 mM Tris (pH
7.5), 1 mM dithiothreitol, 1 mM EDTA, 100 mM KCl, 2 mM MgCl2, 50 μg/ml BSA, and 10%
glycerol], 1 μl recombinant ERα, 1 μg polydeoxyinosinic-deoxycytidylic acid, and 20,000 cpm
probes labeled with [γ-32P]dATP (Amersham, Piscataway, NJ) using polynucleotide kinase
(Roche). For supershift studies and for competition studies, 1 μl ERα HC20-X rabbit polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or an excess unlabeled DNA was added
to the reaction. Protein-DNA complexes were resolved on a 5% native polyacrylamide gel
using 0.5× Tris-borate-EDTA buffer. Gels were then dried and subjected to autoradiography.
ChIP
A total of 2 × 106 GH3/hPrl-luc cells were serum starved for 24 h and treated with 10 nM E2
or 0.1% dimethylsulfoxide (DMSO). Chromatin was cross-linked using 1% formaldehyde for
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10 min at 37 C, and the cells were collected after two washings with PBS and lysed in 200 μl
ChIP lysis buffer [1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1), and protease inhibitor
cocktail (Calbiochem, La Jolla, CA)] on ice for 15 min. All subsequent buffers contained the
protease inhibitor cocktail. The cell suspension was then sonicated for five 30-sec cycles in a
Kerry Pulsatron sonicating bath, with 30 sec on ice between cycles. After centrifugation, 20
μl of the supernatants was retained and used as the input control, and the remainder was diluted
to 2 ml in IP buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH
8.1), 167 mM NaCl]. This diluted fraction was subjected to IP with 4 μg of either anti-Era
antibody (HC20; Santa Cruz), anti-Pit-1 (X-7; Santa Cruz), or nonspecific IgG (Santa Cruz)
overnight after 2 h preclearing at 4 C with 20 μl preimmune IgG (Sigma), 0.05% BSA, 5 μg
sheared salmon sperm DNA, and 5 μl protein A-Dynabeads (Invitrogen). Complexes were
recovered by 2 h incubation at 4 C with 2 μg sheared salmon sperm DNA and 2 μl protein A-
Dynabeads. Precipitates were serially washed for 15 min with 500 μl buffer I [0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 150 mM NaCl), buffer II [0.1% SDS 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 500 mM NaCl), buffer III [0.25 M LiCl,
1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl (pH 8.1)] and then twice
with Tris-EDTA buffer [1 mM EDTA, 10 mM Tris-HCl (pH 8.0)]. Precipitated chromatin
complexes were removed from the beads through a 30-min incubation with 50 μl 1% SDS, 0.1
M NaHCO3, with vortexing each 5 min. This step was repeated twice. Cross-linking was
reversed by an overnight incubation at 65 C. DNA was purified with QIAquick PCR
purification kit (QIAGEN), as indicated by the manufacturer, and used in a PCR with the
following primers: prolactin ERE/Pit-1 forward 5′-AGGCTGCTTTAGATGCATGG-3′ and
reverse 5′-TTCTCTGACCCTGAGCCACT-3′; rat GAPDH forward 5′-
GAAATGGGCTTAGGGGTGAT-3′ and reverse 5′-TTAAGGATGGCCTTGGACTG-3′.
Results
Estradiol activates the hPrl promoter
To assess whether estrogen exerts an effect on the 5000-bp hPrl promoter, GH3/hPrl-luc cells
were treated with increasing doses of E2 and assayed for luciferase activity after 24 h (Fig.
1A). At concentrations of 10−12 M (1 pM) and above, E2 showed a significant induction of
reporter gene activity to a maximal induction of 1.8-fold over untreated cells, with an EC50 of
0.02 nM, suggesting that the 5000-bp hPrl promoter is regulated by E2. Stimulation of GH3/
hPrl-luc cells with 10 nM E2 over time demonstrated a progressive increase with time, reaching
a plateau by 24 h with no further induction observed up to 72 h (Fig. 1B and data not shown).
Using qPCR, we confirmed approximately 4-fold activation by E2 of the endogenous rat Prl
(rPrl) gene in clonal GH3/hPrl-luc cells (Fig. 1C, upper panel) and in primary cultures of
Fischer-344 rat pituitary glands (Fig. 1C, lower panel).
ER-specific antagonists inhibit estradiol induction of the promoter
The selective ER modulator 4-hydroxytamoxifen (4OHT) and the pure estrogen antagonist
ICI-182,780 were used to investigate the ER specificity of the estrogen regulation of the hPrl
promoter. The antagonists were used at the optimal concentrations, determined using ERE-luc
transfected GH3 cells (data not shown), on GH3/hPrl-luc cells treated with 1 nM E2. Treatment
with these antagonists abolished reporter gene induction from the hPrl promoter at
concentrations of 1000 and 10 nM for 4OHT and ICI-182,780, respectively (Fig. 2A), indicating
ER specificity in promoter activation. Dose-response data for the two antagonists showed that
ICI-182,780 but not 4OHT significantly reduced luciferase activity to below basal expression
levels (Fig. 2B), which may be due to proteasomal mediated degradation of the ER by the ICI
antagonist (18). These data suggest a possible role of the ER itself in hPrl transcription,
irrespective of ligand.
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The hPrl promoter has an ERE at −1189 bp
Previous studies on the rPrl promoter have identified an ERE sequence at −1575 bp (19). This
is found adjacent to a Pit-1 binding site within the distal enhancer sequences of the promoter.
The corresponding sequence in the hPrl promoter has previously been reported to be
functionally different, with no evidence of synergistic cooperation between ER and Pit-1, in
contrast to the rat gene (20). The corresponding sequence in the hPrl promoter differs from a
consensus ERE sequence by two base pairs, one for each half-site. These two altered bases
also diverge from the consensus ERE in the rPrl promoter, although the substitutions are
different. In addition, two of the three less conserved intermediate bases between the two half-
sites are also altered between the rat and human sequences (Fig. 3A), which has led some
authors to suggest that this degeneracy leads to loss of ERE function in the hPrl promoter
(20). Several truncated hPrl promoter-luciferase constructs ranging from −4.8 to −0.8 kb were
constructed and assessed for E2 responsiveness. All constructs were responsive to E2 except
for the shortest (−0.8 kb), indicating estrogen-responsive sequences to be located between
−1779 and −828 bp, which includes the putative ERE sequence (Fig. 3B).
To confirm whether this putative ERE at −1189 bp was functional, we performed site-directed
mutagenesis to disrupt the sequence, and the resulting construct was transiently transfected
into pituitary GH3 cells (Fig. 3C). Mutation of this sequence resulted in loss of promoter
activation by 10 nM E2, consistent with its constituting the functional ERE in the hPrl gene. In
control experiments, we found that forskolin, which activates adenylyl cyclase and mediates
promoter activation through proximal sequences, stimulated both the wild-type and mutant
promoters similarly. Surprisingly, TNFα stimulation of promoter activity was completely
abolished by the ERE mutation (Fig. 3C). Previously in our lab, TNFα has been shown to
mediate hPrl promoter stimulation through activation of NFκB (9), but despite mutagenesis of
several potential NFκB binding sites in the promoter, a critical TNFα-responsive element was
not previously defined. The present results suggest that TNFα action may in fact be mediated
through a functional ERE.
EMSAs were used to assess whether the hPrl ERE sequence was able to bind ER (Fig. 3D).
When incubated with recombinant ERα, the consensus ERE sequence from the vitellogenin
A2 gene gave a strong retarded band that was supershifted using the anti-ERα antibody HC20,
competed by an excess of unlabeled homologous DNA sequence, but not competed by a
nonspecific oligonucleotide (Fig. 3D, left panel). When the same assay was performed using
the hPrl ERE sequence, the same general binding pattern was observed with a clear but weaker
retarded DNA-protein complex that was supershifted by the anti-ERα antibody and displayed
sequence-specific competition (Fig. 3D, right panel). ChIP assays showed recruitment of Pit-1
to this promoter region and confirmed binding of ERα, the level of which appeared to increase
when cells were treated with E2 treatment (Fig. 3E).
Interactions between estradiol and TNFα signaling
Due to the finding that TNFα activation of the hPrl promoter was abolished by mutation of the
−1189-bp ERE, we investigated the possibility that there is an interaction between estrogen
and TNFα signaling. When cells were cotreated with E2 in combination with TRH, FGF2, or
forskolin, there was increased induction of the promoter compared with either stimulus alone,
roughly equivalent to the sum of the two individual stimulations (data not shown). On the other
hand, when TNFα and E2 were used to treat GH3/hPrl-luc cells, a synergistic induction of
reporter gene activity was observed. In time-course experiments, E2 and TNFα cotreatment
induced synergistic stimulation within 24 h, with more marked synergy apparent by 48–72 h
(Fig. 4, A and B). Cell proliferation assays showed that this increase in luciferase activity was
not attributable to increased cell number (data not shown). This synergistic transcriptional
induction appeared to be specific to the hPrl promoter, because E2 and TNFα costimulation
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resulted in either no effect or an antagonistic combinatorial effect, respectively, when pituitary
GH3 cells were studied after transfection with either a consensus NFκB-luc reporter construct
or a consensus ERE-luc construct (Fig. 4C). The synergistic effect was completely abolished
when cells were cotreated with the ER antagonists 4OHT and ICI-182,780 (Fig. 4B).
Transcription of the endogenous rPrl gene was analyzed by qPCR to assess whether the
synergistic interaction of ER and NFκB signaling was an effect confined to the hPrl promoter
in the stably transfected cell line. A small additive effect between the two stimuli was observed
at 24 h (Fig. 4D, left panel), but a large synergistic interaction (∼83-fold) was seen after 48 h
treatment (Fig. 4D, right panel), indicating that the rPrl promoter was affected in a similar
manner to the human gene by the combination of these stimuli.
Discussion
Estrogen is regarded as an important physiological signal in the regulation of the prolactin gene
in man, but previous studies have not identified the mechanisms of regulation (20,21). Here
we have identified a degenerate ERE sequence within the human prolactin promoter at −1189
bp relative to the transcription start site, which differs significantly from the rPrl ERE, although
it is located within the corresponding enhancer sequence (20,21). The hPrl ERE differs from
a consensus sequence by two bases, one in each half-site, and has lower affinity for binding
ERα as shown by in vitro EMSAs. However, ChIP assays clearly showed this ERE to recruit
ERα in vivo both in the presence and absence of E2, with possible increase in recruitment after
stimulation. This particular ERE sequence also appears to be essential both for the TNFα-
induced, NFκB-mediated activation of the hPrl promoter and for the marked synergistic
transcriptional effects of estrogen and TNFα that we have identified. Thus, this ERE sequence
in the hPrl gene appears to be a target for two converging signaling pathways and may be
important for the physiological interpretation of multiple endocrine and stress signals in vivo.
We confirmed that a putative hPrl ERE sequence is indeed a functional estrogen-responsive
sequence and suggest that the relatively small effect of E2 alone and the unusual marked
synergistic effects observed between E2 and TNFα may be related to the structure of the
sequence. The ERE described in the rPrl promoter (19) and the ERE described in this paper
both differ from the consensus ERE at the same two bases, but one of these is different in the
human sequence, and the intermediate three bases are also different (Fig. 3). Two or more base
pair changes from the consensus ERE reduce ERα binding affinity (22) but can lead to altered
function through different cofactor recruitment. For example, a coactivator of ERα on the pS2
promoter is steroid receptor coactivator (SRC)-3, involving an ERE with two base changes in
the 3′ half-site, whereas the progesterone receptor promoter contains an ERE with four base
pair changes in the 3′ half-site and recruits SRC1 and cAMP response element binding protein-
binding protein (23). This suggests that the hPrl ERE, with a unique nucleotide sequence, may
allow altered function in the actions of ERα for this target gene. The ER may exert some effects
on transcription even in the relatively unliganded state. ChIP studies (24,25) indicate that
ERα binds to DNA response elements when unliganded, and it has recently been reported that
ERα is associated with the rPrl distal enhancer in the absence of ligand (26). The pure ER
antagonist ICI-182,780 caused a reduction in basal hPrl promoter activity (Fig. 2B) and is
known to lead to ERα degradation (27), which implies a role for unliganded ERα in the
background level of activation of the hPrl promoter even in the absence of specific stimulation
by E2.
The pituitary-specific transcription factor Pit-1 is likely to have an important role in estrogen
action on the Prl gene (28,29). We found that Pit-1 bound to the hPrl gene region containing
the −1189-bp ERE in both the presence and absence of E2 (Fig. 3E), which concurs with
previous studies on the rPrl promoter (30) and may indicate that Pit-1 and ER are involved in
the formation of a multiprotein complex at this site. Liu et al. (30) did not detect changes in
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Pit-1 association/dissociation with the rPrl promoter after treatment with various hormones or
agents. The authors proposed that Pit-1 functions in part as a promoter-bound docking site for
co-regulatory complexes recruited by diverse hormone signals. Furthermore, it has been
reported that Pit-1 is essential for the nucleosomal positioning within the rPrl promoter and
contributed to the mechanisms that establish the cell-specific chromatin structure of the Prl
gene (31). Previous work has suggested that ERα and Pit-1 exert synergistic transcriptional
effects on the rat but not the hPrl promoter (20). However, that study was performed using
chimeric promoter fragments expressed in the human uterine cell line SKUT-1B-20. This cell
line does not endogenously express Pit-1 or ERα, and therefore the expression of these proteins
was manipulated by transient transfection with expression vectors. The level of transcription
factor expression is normally highly regulated and the available concentration of transcription
factor is therefore likely to influence gene regulation (32,33). The cell lines we used are derived
from somatolactotroph cells of the anterior pituitary and are likely to replicate endogenous
levels of protein expression more authentically than the SKUT-1B-20 cell line. By using
constructs containing natural intact promoter sequences, our cell model may therefore represent
more accurately the regulation of the hPrl gene than previous studies.
TNFα has been shown to activate hPrl gene transcription via NFκB signaling (9). The precise
DNA sequences involved in this activation were not identified despite mutagenesis of several
putative NFκB binding sites. In the present study, mutagenesis of the hPrl ERE completely
blocked not only the activating effect of estrogen but also that of TNFα, indicating that NFκB
activation of the promoter is mediated through the ERE and suggesting an interaction between
the two signaling pathways. Steroid hormone receptors, including ERα, have long been
described to interact with NFκB, usually in an antagonistic fashion, with the mechanism of
antagonism depending on both the cell type (34) and the promoter (35). However, in our system,
cotreatment of TNFα and E2 in GH3/hPrl-luc cells led to a synergistic activation of reporter
gene activity. This may be a promoter-specific effect whereby ER and NFκB can be members
of the same regulatory complex due to the unique ERE sequence found at −1189 bp. The qPCR
analysis confirmed a similar synergistic interaction between E2 and TNFα signaling in
activation of endogenous rPrl gene expression. Such a synergistic interaction between these
signals was not, however, seen using either consensus ERE or NFκB response elements linked
to luciferase reporter genes in GH3 cells, indicating that the effect was Prl promoter specific
(Fig. 4C). In fact, an antagonistic effect was observed on the transfected ERE-luc construct,
reminiscent of the widely reported mutual antagonism of NFκB and nuclear hormone receptors
observed in other systems (35,36).
The synergistic activation of the hPrl promoter by E2 and TNFα could be blocked by tamoxifen,
with a reduction of activity to the level of stimulation induced by TNFα alone, implying that
the interactive effect of E2 and TNFα requires the AF-2 domain of ERα and potentially requires
recruitment of coactivators (37,38). ICI-182,780 is regarded as a pure ER antagonist and can
lead to proteasomal degradation of the ER (27). Reid et al. (39) reported constitutive, low-level
recruitment of ERα to the pS2 promoter that increased upon treatment with E2. However, on
treatment of cells with ICI-182,780, ER recruitment was lost within 3 h (irrespective of the
presence or absence of E2), with evidence for its proteasomal degradation, and such receptor
turnover may be an integral feature of estrogen signaling (39). In the present work in pituitary
cells, the ICI antagonist not only blocked the synergistic effect of E2 and TNFα but also reduced
promoter activity to well below basal levels, suggesting that ER itself is essential to maintain
Prl basal expression. In view of these findings, we propose that the TNFα stimulatory effects
on the hPrl promoter require the presence of ERα, irrespective of the presence of estrogen, and
that addition of E2 ligand permits further increases in transcription. Given the promoter-
specific nature of this cross-talk, Pit-1 may be necessary to facilitate such an interaction,
although this requires more investigation.
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Few studies describe positive interactions between ERα and NFκB. Rubio et al. (40) showed
ER and NFκB to have combinatorial effects on genes controlling cell division in ER-positive
breast cancer cells, with ChIP assays showing recruitment of both ERα and NFκB to the cyclin
D1 promoter. Although direct interaction between the two proteins was not determined, the
coactivator SRC3, which has been described as a coactivator in gene activation by both ER
(41) and NFκB (42), was found to be interacting with both the NFκB subunit p65 and ERα in
co-IP experiments, suggesting that interactions between these two signaling pathways may be
indirect and require a complex formation with other transcription factors (40). Wissink et al.
(43) showed the serotonin 1A receptor promoter to be synergistically activated by p50/p65
(NFκB) and ERα in COS-1 cells. The effect occurred with unliganded ER and was further
increased upon addition of E2. Interestingly, the synergistic interaction observed on the
serotonin 1A receptor promoter was mediated through degenerate NFκB binding sites, and not
an ERE as in the hPrl promoter.
The role of TNFα within the pituitary is unknown but may mediate paracrine or inflammatory
effects (9). E2 is reported to have several different endocrine effects within the pituitary,
including regulation of multiple genes and secretion of gene products (7). Here we show the
signaling pathways from these two important stimuli to interact, indicating that TNFα signaling
may be an important amplifier of estrogen response. It would be of interest to study this in
vivo to analyze fully the endocrine role of TNFα in modulating other signaling pathways in the
context of the full endogenous locus.
In summary, we have identified an ERE in the hPrl gene and have found a novel synergistic
interaction between estrogen and cytokine signaling that facilitates increased expression of
hPrl. The ERE is unusual and is necessary also for TNFα activation of the gene and to mediate
the synergistic interaction between these two converging signal pathways. It is likely that
estrogen, while having a relatively small effect in isolation, is a critical factor that may
dramatically amplify prolactin expression in response to other endocrine or paracrine signals
in the pituitary.
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Fig. 1.
E2 activates the hPrl promoter in GH3/hPRL-LUC cells. Serum-starved GH3/hPrl-luc cells
were stimulated with E2, lysed at relevant time points, and assayed for luciferase activity. A,
Increasing doses of E2 were used ranging from 0–100 nM for 24 h; B, 10 nM E2 was used and
cells lysed at various time points for assay. The dotted line indicates baseline determined from
0.1% DMSO control. C, To verify these cells as a model system for E2-induced Prl gene
expression, RNA was extracted, reverse transcribed, and subjected to qPCR for rPrl expression,
using rat cyclophilin as an internal control (upper panel). The qPCR was also performed on
cDNA from Fischer rat pituitary primary cells. *, P < 0.05; **, P < 0.01; ***, P < 0.001,
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Student's t test. The data are the mean ± SD of four independent experiments, each with four
replicates.
Adamson et al. Page 13
Endocrinology. Author manuscript; available in PMC 2008 August 1.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Fig. 2.
Effects of antagonists on the hPrl promoter in GH3/hPRL-LUC cells. A, Serum-starved GH3/
hPrl-luc cells were treated with the indicated stimuli at concentrations of 1 nM E2, 1000 nM
4OHT, and 10 nM ICI-182,780 (ICI) for 24 h. After treatment, cells were lysed and assayed for
luciferase activity. The dotted line indicates baseline determined from 0.1% DMSO control.
B and C, Starved GH3/hPrl-luc cells were treated with either vehicle (0.1% DMSO) or the
indicated concentrations of 4OHT (A) or ICI (B) for 24 h, lysed, and assayed for luciferase
activity. ns, Not significant; ***, P < 0.001, Student's t test. The data are the mean ± SD of three
independent experiments, each with four replicates.
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Fig. 3.
Identification of an ERE in the hPrl promoter. A, Potential EREs within the hPrl promoter are
shown by white rectangles, as identified by AliBaba 2.1 (44). Pit-1 binding sites are shown by
black rectangles. The arrow indicates the ERE with the closest match to the consensus ERE
and corresponds to a previously described ERE within the rPrl promoter (19). Altered bases
from consensus are indicated in italics. B, Deletion constructs of the hPrl5000luc plasmid were
transfected into GH3 cells. Transfected cells were serum starved for 24 h and treated with 1
nM E2 for 24 h, lysed, and assayed for luciferase activity. The dotted line indicates baseline
determined from 0.1% DMSO control. ns, Not significant; *, P < 0.001. C, The −1189-bp ERE
site was mutated to abolish any similarity to a consensus sequence. The mutated and wild-type
promoter luciferase constructs were transfected into GH3 cells, serum starved for 24 h, treated
with 1 nM E2 for 24 h, lysed, and assayed for luciferase activity. D, Binding of ER to a consensus
vitellogenin A2 ERE (vERE; left panel) and the −1189-bp ERE of the hPrl promoter (right
panel) by EMSA. Specificity was confirmed through antibody supershift (using anti-ERα
HC20; Santa Cruz) and competition through excess of unlabeled consensus sequence and
nonspecific (NS) DNA sequence. Arrows indicate retarded bands and supershift. E, Serum-
starved cells were treated for 24 h with either vehicle (0.1% DMSO) or E2 (10 nM). Cells were
fixed in 1% formaldehyde and subjected to ChIP with either a nonspecific IgG antibody, Pit-1-
specific antibody X-7, or ERα-specific antibody HC20. DNA was isolated and amplified using
primers flanking the hPrl ERE or a nonspecific rGAPDH promoter sequence. Data shown are
representative of three separate experiments.
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Fig. 4.
E2 and TNFα synergistically activate the hPrl promoter. A, Serum-starved GH3/hPrl-luc cells
were treated with either a 0.1% DMSO control, 1 nM E2, 10 ng/ml TNFα, or E2 and TNFα
together for various times, lysed, and assayed for luciferase activity. B, Serum-starved GH3/
hPrl-luc cells were treated as indicated [1 nM E2, 10 ng/ml TNFα, 1000 nM 4OHT, and 10 nM
ICI-182,780 (ICI)], lysed, and assayed for luciferase activity after 24, 48, or 72 h. The dotted
line indicates baseline determined from 0.1% DMSO control (note the change in the y-axis
scale). C, ERE-luc and NFκB-luc constructs were transfected into GH3 cells (left and right
panels, respectively). Transfected cells were serum starved for 24 h, treated as indicated for
24 h, lysed, and assayed for luciferase activity. ns, Not significant; ***, P < 0.001 examined
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by two-way ANOVA. The data are the mean ± SD of three independent experiments, each with
four replicates. D, Serum-starved GH3/hPrl-luc cells were untreated as indicated for 24 h
(left) or 48 h (right). Cells were harvested, and RNA was prepared, reverse transcribed, and
subjected to qPCR analysis using primers to examine the expression of rPrl transcript. Data
were normalized using expression of the housekeeping gene cyclophilin. ns, Not significant;
***, P < 0.001 examined by two-way ANOVA. The data are the mean ± SD of four independent
experiments, each with four replicates.
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